Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y2S2
UPID:
CRYL1_HUMAN
Alternative names:
L-gulonate 3-dehydrogenase
Alternative UPACC:
Q9Y2S2; A0PJ43; B3KN92; Q0VDI1; Q7Z4Z9; Q9P0G7
Background:
Lambda-crystallin homolog, also known as L-gulonate 3-dehydrogenase, plays a pivotal role in metabolic processes. It showcases high L-gulonate 3-dehydrogenase activity, alongside lower dehydrogenase activity towards L-3-hydroxybutyrate (HBA) and L-threonate. This enzyme's unique catalytic capabilities underline its importance in the biochemical pathways it participates in.
Therapeutic significance:
Understanding the role of Lambda-crystallin homolog could open doors to potential therapeutic strategies. Its enzymatic functions suggest a significant, yet unexplored, potential in metabolic disorder treatments and beyond.